Drug Trial Radar · NCT06481306
A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease
Last checked: Nov 19, 2026Latest source record: Aug 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
224
Planned (sponsor's estimate)
Start
Jul 17, 2024
Primary completion
Jan 6, 2027
Study completion Nov 16, 2027
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Jul 1, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics, pH and food effect, and preliminary efficacy of BMS-986470 in healthy volunteers and participants with sickle cell disease.
Conditions
- Anemia, Sickle Cell
- Healthy Volunteers
Interventions
BMS-986470Drug
Specified dose on specified days
PlaceboDrug
Specified dose on specified days
FamotidineDrug
Specified dose on specified days
PantoprazoleDrug
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with adverse events (AEs)Time frame: Up to 26 months
- Number of participants with serious adverse events (SAEs)Time frame: Up to 26 months
- Number of participants with AEs meeting protocol-defined Dose Limiting Toxicity (DLT) criteriaTime frame: Up to 26 months
- Number of participants with AEs leading to discontinuationTime frame: Up to 26 months
- Number of deathsTime frame: Up to 26 months
- Proportion of participants achieving HbF ≥ 10%Time frame: Up to 28 days after last dose
- Proportion of participants achieving HbF ≥ 20%Time frame: Up to 28 days after last dose
- Proportion of participants achieving HbF ≥ 30%Time frame: Up to 28 days after last dose
Locations
32 sites in 5 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama · Recruiting
University of California San Diego - La Jolla
La Jolla, California · Recruiting
UCSF Benioff Children's Hospital Oakland
Oakland, California · Recruiting
Yale-New Haven Hospital
New Haven, Connecticut · Recruiting
Winship Cancer Institute of Emory University
Atlanta, Georgia · Recruiting
Local Institution - 0034
Chicago, Illinois · Not yet recruiting
Local Institution - 0001
Lenexa, Kansas · Active not recruiting
Local Institution - 0064
Baltimore, Maryland · Not yet recruiting
Local Institution - 0024
Boston, Massachusetts · Not yet recruiting
Boston Medical Center
Boston, Massachusetts · Recruiting
Local Institution - 0030
St Louis, Missouri · Not yet recruiting
Local Institution - 0033
Greenville, North Carolina · Not yet recruiting
Local Institution - 0028
Cleveland, Ohio · Not yet recruiting
Local Institution - 0029
Philadelphia, Pennsylvania · Not yet recruiting
Thomas Jefferson University - Medicine/GI and Hepatology
Philadelphia, Pennsylvania · Recruiting
Local Institution - 0032
Pittsburgh, Pennsylvania · Not yet recruiting
Local Institution - 0027
Greenville, South Carolina · Not yet recruiting
Inova Schar Cancer Institute
Fairfax, Virginia · Recruiting
Virginia Commonwealth University (VCU) Medical Center
Richmond, Virginia · Recruiting
Local Institution - 0050
Vancouver, British Columbia, Canada · Not yet recruiting
Local Institution - 0061
Créteil, France · Not yet recruiting
Assistance Publique Hôpitaux de Marseille - Hôpital de la Timone
Marseille, France · Recruiting
Hôpital Universitaire Necker Enfants Malades
Paris, France · Recruiting
CHU Strasbourg-Hautepierre
Strasbourg, France · Recruiting
Local Institution - 0037
Padua, Italy · Not yet recruiting
Local Institution - 0009
Verona, Italy · Not yet recruiting
Local Institution - 0011
Milan, Lombardy, Italy · Not yet recruiting
Local Institution - 0005
Leeds, United Kingdom · Not yet recruiting
Local Institution - 0047
London, United Kingdom · Not yet recruiting
University Hospitals Sussex NHS Foundation Trust
East Sussex, Brighton And Hove, United Kingdom · Recruiting
Local Institution - 0044
London, Greater London, United Kingdom · Not yet recruiting
King's College Hospital
London, London, City of, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.